Quick Facts
  • pin location icon
    Primary Location:
    UCSF Helen Diller Family Comprehensive Cancer Center
  • wavy circle icon with check mark inside
    Expertise:
    Palliative Care
    Multimodal Therapy
  • magnifying glass with heart icon
    Speciality:
    Hematology/Oncology
  • gender symbols interlocked icon
    Gender:
    Male
  • chat box with different language translations icon
    Language:
    English, Spanish, French
  • certificate with a ribbon icon below
    Med School:
    George Washington University School of Medicine

Dr. Thierry Jahan often recommends that his patients obtain several forms of treatment, known as a multimodal approach, which blends several treatments to give patients the best possible chance for recovery.

Another important focus of Dr. Jahan’s practice is palliative care. When patients are ineligible for potentially curative treatments like surgery, chemotherapy or radiation therapy, palliative treatments can help alleviate painful symptoms and improve quality of life. Dr. Jahan’s commitment to providing this comforting care earned him the Friend of the Palliative Care Service Award in 2006.

Doctor Jacques Fontaine and Doctor Virginia Wolf
Find a Top Mesothelioma Doctor
Gain access to top mesothelioma doctors and get help scheduling appointments.

Exploring Multimodal Therapies for Mesothelioma & Lung Cancer

A significant amount of Dr. Jahan’s research explores multimodal therapies for lung cancer and mesothelioma. He has lectured nationally and internationally on these topics and contributed to numerous book chapters and journal articles, including a 2012 National Comprehensive Cancer Network overview of clinical practice guidelines in oncology for pleural mesothelioma.

Dr. Jahan has also served as primary investigator in several clinical trials, including a phase II clinical trial that evaluates the safety and effectiveness of the monoclonal antibody drug MM-121 in patients with non-small cell lung cancer. He also directed the research in a randomized phase II study that aims to determine the potential benefits of maintenance therapy with Alimta for pleural mesothelioma patients who have completed first-line chemotherapy.

A hands-on residency and fellowship at Cedars Sinai Medical Center in Los Angeles provided Dr. Jahan with the medical experience he now uses in his own practice. He initially joined the team at the University of California’s Division of Hematology and Oncology as a clinical fellow and worked his way up to his current positions.

Dr. Jahan is well known for the compassion he has for his patients. When a person is told that he or she has cancer, they are stunned into silence, said Bonnie J. and Anthony Addario, who named Dr. Jahan Endowed Chair in Thoracic Oncology for the Department of Surgery at University of California, San Francisco. Thierry has a way of delivering that news with hope, compassion and a great sense of what the patient is feeling. He not only delivers world-class treatment, he also delivers hope.

Dr. Jahan’s Publications

In 2002, Jahan published his only article discussing mesothelioma. The article, “Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma,” appeared in the Journal of Thoracic Cardiovascular Surgery.